Novo Nordisk A/S (NVO) Upgraded to Outperform at BNP Paribas
Several other brokerages have also recently weighed in on NVO. Citigroup Inc. reiterated a buy rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Zacks Investment Research upgraded Novo Nordisk A/S from a sell rating to a hold rating in a research report on Monday, July 11th. Goldman Sachs Group Inc. cut Novo Nordisk A/S from a conviction-buy rating to a buy rating in a research report on Tuesday, June 28th. Bank of America Corp. cut Novo Nordisk A/S from a buy rating to a neutral rating in a research report on Monday, August 8th. Finally, HSBC upgraded Novo Nordisk A/S from a reduce rating to a hold rating in a research report on Wednesday, August 31st. Six research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of Buy and an average price target of $61.33.
Novo Nordisk A/S (NYSE:NVO) opened at 46.12 on Tuesday. Novo Nordisk A/S has a 52-week low of $44.04 and a 52-week high of $59.00. The company has a market capitalization of $116.97 billion, a P/E ratio of 21.57 and a beta of 0.74. The firm has a 50-day moving average price of $48.91 and a 200 day moving average price of $53.35.
The company also recently declared a dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were paid a dividend of $0.326 per share. The ex-dividend date of this dividend was Thursday, August 11th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 48.82%.
Large investors have recently modified their holdings of the company. Advisory Services Network LLC raised its stake in shares of Novo Nordisk A/S by 28.8% in the second quarter. Advisory Services Network LLC now owns 2,238 shares of the company’s stock valued at $120,000 after buying an additional 500 shares during the period. J.Safra Asset Management Corp bought a new stake in Novo Nordisk A/S during the second quarter worth $127,000. Ranger International Management LP raised its stake in Novo Nordisk A/S by 49.1% in the second quarter. Ranger International Management LP now owns 2,430 shares of the company’s stock worth $131,000 after buying an additional 800 shares during the period. Cribstone Capital Management LLC bought a new stake in Novo Nordisk A/S during the second quarter worth $159,000. Finally, Tower Research Capital LLC TRC raised its stake in Novo Nordisk A/S by 2,998.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,098 shares of the company’s stock worth $167,000 after buying an additional 2,998 shares during the period. 7.33% of the stock is owned by hedge funds and other institutional investors.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.